Demographic Characteristics and Disease Subtypes of Patients with Acute Myeloid Leukemia across Large Community Health Systems in the US
Author(s)
Lorenzo R1, Pomerantz D2, Subramanian V2, Tran M2, Rioth M2, Berry A2, Walters S2, Wolf F2, Sommers C2, Chen W2, Wolfe T2, Brown T2
1Syapse, Palm Beach Gardens, FL, USA, 2Syapse, San Francisco, CA, USA
Presentation Documents
OBJECTIVES: Community health systems (CHSs) treat over 50% of patients with cancer across the US. The profile of patients with Acute Myeloid Leukemia (AML) seen in CHSs within the US are not widely published. This analysis describes the demographic characteristics and disease subtypes of patients with AML treated across a sample of CHSs. METHODS: A retrospective analysis was performed utilizing the Syapse Learning Health Network (SLHN), an electronic medical record (EMR) derived database that collects cancer care data from multiple care settings that make up the US CHSs across 33 states, 450+ hospitals and 1,900+ community employed oncologists. Patients aged >18 yo at AML diagnosis from January 1, 2010 - June 22, 2021 were identified from the SLHN using ICD-10 codes. APL was deliberately excluded. Data elements were derived from both structured and unstructured sources, via direct integrations and Certified Tumor Registrars, respectively, and are descriptively summarized. RESULTS: 1,001 patients from the SLHN were included in the analysis. Patient demographics included: median age of 69 years at AML diagnosis; 46% female and 54% male; 78% White, 9% Black, 2% Asian, 11% other/unknown; 4% of Hispanic/Latino ethnicity. According to WHO Classification, 36% of patients were classified at diagnosis as AML with myelodysplasia related changes, 21% were AML Not Otherwise Specified (NOS), 18% were classified as therapy-related myeloid neoplasms, and 8% were AML with recurrent genetic mutations. CONCLUSIONS: Patients with AML treated in CHSs within the SLHN were elderly, white and skewed slightly more male, with a relatively high percentage of patients having myelodysplastic features. Further evaluation is needed to assess whether the real world group of patients with AML and myelodysplasia has a worse outcome.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSB413
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Oncology